FDA OKs new agent to block chemotherapy-induced neutropeniaNovember 29, 2023Mixed TopicsAggressive LymphomasB Cell LymphomaDLBCLHodgkin LymphomaIndolent LymphomaMantle Cell Lymphoma
DLBCL treatment options: CAR T outperforms ASCTNovember 3, 2023DLBCLCellular TherapyTransplantNon-Hodgkin Lymphoma
Antibody shows promise in preventing GVHDAugust 8, 2023TransplantMixed TopicsMultiple MyelomaNon-Hodgkin LymphomaHodgkin LymphomaB Cell LymphomaCLL
ESMO helps hematologists assess new cancer drugsJune 28, 2023Mixed TopicsCellular TherapyCMLCLLAggressive LymphomasALLAML
Multiprong strategy makes clinical trials less WhiteJune 23, 2023Diversity in MedicinePatient & Survivor CareDLBCLALLAggressive LymphomasAMLB Cell Lymphoma
CBSM phone app eases anxiety, depression in cancer patientsJune 23, 2023Patient & Survivor CareDLBCLAggressive LymphomasALLAMLCLLCML
Huge underuse of germline testing for cancer patientsJune 22, 2023Patient & Survivor CareDLBCLAggressive LymphomasALLAMLB Cell LymphomaCellular Therapy
DEI training gives oncology fellows more confidenceJune 22, 2023Diversity in MedicineDLBCLALLAggressive LymphomasAMLB Cell LymphomaCLL
Drugmakers are abandoning cheap generics, and now U.S. cancer patients can’t get medsJune 22, 2023Patient & Survivor CareDLBCLAggressive LymphomasALLAMLAnemiaB Cell Lymphoma
Widespread carboplatin, cisplatin shortages: NCCN surveyJune 9, 2023Patient & Survivor CareMixed TopicsAggressive LymphomasALLAMLB Cell LymphomaCLL
`Remarkable’: CAR T therapy for CLL/SLLJune 8, 2023CLLB Cell LymphomaNon-Hodgkin LymphomaCellular Therapy
PMBCL: Postremission, patients may safely skip radiationJune 6, 2023B Cell LymphomaDLBCLNon-Hodgkin Lymphoma
Number of cancer survivors with functional limitations doubled in 20 yearsMay 11, 2023Patient & Survivor CareDiversity in MedicineMixed TopicsDLBCLALLAMLAnemia
